Skip to main
ZURA

ZURA Stock Forecast & Price Target

ZURA Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Zura Bio is deemed a strong investment opportunity for this analyst, as the clinical-stage biotechnology company specializes in developing medicines for autoimmune and inflammatory diseases with high unmet medical needs. While external funding may pose risks for the company, Zura Bio's focus on executing phase 3 trials for its three clinical-stage product candidates and its consideration of partnerships give confidence in its future success. Furthermore, with a strong management team led by Dr. Nistala, who has extensive experience in translational medicine and clinical trial design, and sufficient cash to fund operations through 2027, Zura Bio is well positioned to achieve its goals.

Bears say

Zura Bio is currently facing various risks, including clinical, intellectual property, and regulatory/commercial risks, which may limit their potential for revenue growth and stock price potential. While the company is conducting Phase 2 trials for their potential treatments, there is no guarantee of success and their financial results and fundraising efforts may not be enough to overcome these risks. The company also faces competition in the market and the founder's experience may not be enough to ensure success in this fast-paced industry.

ZURA has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zura Bio Ltd (ZURA) Forecast

Analysts have given ZURA a Buy based on their latest research and market trends.

According to 5 analysts, ZURA has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zura Bio Ltd (ZURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.